Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma? (Q40913807)

24 September 2017

Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma? (English)

1 reference

24 September 2017

M Hernberg

1

1 reference

PubMed ID

9093710

24 September 2017

T Muhonen

series ordinal

2

1 reference

PubMed ID

9093710

24 September 2017

S Pyrhönen

series ordinal

3

1 reference

24 September 2017

1 January 1997

1 reference

24 September 2017

1 reference

24 September 2017

8

1 reference

24 September 2017

1

1 reference

24 September 2017

71-77

1 reference

The natural history of metastatic renal cell carcinoma: a computer analysis

24 September 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Procedural guidelines for performing immunophenotyping by flow cytometry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Immunophenotyping specimens from HIV-infected persons: laboratory guidelines from the Centers for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008293117223

7 January 2021

Identifiers

DOI

10.1023/A:1008293117223

1 reference

24 September 2017

1 reference

PubMed ID

9093710